/
BBLG
$1.38-$0.02 (-1.43%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.5M
2M shares
52-week range
$1.05 – $4.13
11% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
19.37%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-7328.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $96 | $50 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$96 | −$50 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $104.5K | $1.1M | $340.7K | $82.0K | $1.6M | $6.9M | $2.1M | $1.1M |
| Operating income | −$2.8M | −$2.4M | −$825.0K | −$1.1M | −$3.7M | −$9.4M | −$4.2M | −$3.2M |
| EBITDA | −$2.8M | −$2.4M | −$825.0K | −$805.6K | −$752.9K | $479.6K | $107.2K | −$3.1M |
| Net income | −$4.4M | −$3.4M | −$1.8M | −$1.6M | −$1.5M | −$8.9M | −$4.1M | −$3.1M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -3173.58 | -66.97 | -35.68 | -37.35 | -31.20 | -34.01 | -4.83 | -2.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.52 | $-1.52–$-1.52 | 1 |
| 2027 | $0 | $-1.26 | $-1.26–$-1.26 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.22
Price
$1.38
Implied upside
+205%
Peer comparison
Bone Biologics Corp Common Stock
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
www.bonebiologics.com- Employees
- 2
- IPO / List date
- Nov 27, 2015
- HQ
- BURLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds BBLG.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BBLG as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-10 | 1-for-6reverse |
| 2023-12-20 | 1-for-8reverse |
| 2023-06-07 | 1-for-30reverse |
| 2021-10-13 | 1-for-2.5reverse |
| 2018-07-24 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded BBLG yet.
